EMA begins rolling review of Russian Covid-19 vaccine

The EMA's human medicines committee has begun the review based “on results from laboratory studies and clinical studies in adults

A Russian medical worker administers a shot of Russia's Sputnik V coronavirus vaccine in Moscow File picture: AP Photo/Pavel Golovkin

The European Medicines Agency has started a “rolling review” of Russia’s Covid-19 vaccine.

Interim data – published last month – from the phase three trial of the Russian vaccine, Gam-COVID-Vac (Sputnik V), suggests a two-dose regimen of the vaccine offers 91.6% efficacy.